/
Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (Bio-Techne, we, our, us or the Company), develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. Our broad product portfolio and application expertise enables scientific investigations into biological processes and molec…
Operating margin is thin at 8.38%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 5.2%, steady but not accelerating. Margins contracted 9.4pp, which offsets some of the top-line progress.
ROIC dropped from 7.70% to 3.18%, capital efficiency is deteriorating. Operating margin contracted 9.4pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$1.21B
▲ +5.2% YoY
Net Income (TTM)
$110M
▼ -56.3% YoY
Op. Margin
12.70%
▼ -9.4pp YoY
ROIC
4.91%
▼ -4.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$270M
▲ +8.7% YoY
Op. Cash Flow (TTM)
$295M
▼ -3.8% YoY
Net Debt
$81M
Cash & Equiv.
$210M
5Y CAGR: +10.5%
5Y CAGR: +10.8%
Continue Research